In Vivo Gene Delivery Using Exosomes Engineered to Contain AAV Improves Transduction Efficiency and Resists Neutralizing Antibodies

被引：0
|
作者：
McConnell, Russell [1 ]
Lule, Sevda [1 ]
Zi, Tong [1 ]
Jang, Su Chul [1 ]
Noyes, Aaron [1 ]
Sathy, Sriram [1 ]
机构：
[1] Codiak BioSci, Cambridge, MA USA
来源：
MOLECULAR THERAPY | 2023年 / 31卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
461
引用
收藏
页码：237 / 238
页数：2
相关论文
共 50 条
  • [41] Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors
    Halbert, CL
    Miller, AD
    McNamara, S
    Emerson, J
    Gibson, RL
    Ramsey, B
    Aitken, ML
    HUMAN GENE THERAPY, 2006, 17 (04) : 440 - 447
  • [42] Comparative assessment of the transduction efficiency and safety associated with the delivery of AAV9-GFP vector via lumbar puncture to cynomolgus macaques with and without anti-AAV9 pre-existing antibodies
    Guibinga, Ghiabe H.
    Do, Janet
    Chu, Binh
    Gu, Yin
    Kikkawa, Rie
    Li, Xiaoguang
    Ozsolak, Fatih
    Maclachlan, Timothy
    MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2024, 32 (04)
  • [43] Bio-Engineering of Adeno-Associated Virus Serotype (AAV)-2 Capsid at Serine/Threonine Residues Improves Its Transduction Efficiency Both In Vitro and In Vivo
    Hareendran, Sangeetha
    Hussain, Mansoor
    Gadkari, Rupali A.
    Govindarajan, Sudha
    Sen, Dwaipayan
    Balakrishnan, Balaji
    SathishKumar, Yesupatham
    Kalaivani, Vaani
    Ramakrishna, Banumathi
    Srivastava, Arun
    Srivastava, Alok
    Jayandharan, Giridhara Rao
    MOLECULAR THERAPY, 2012, 20 : S47 - S48
  • [44] Gene delivery using AAV8 in vivo for disease stabilization in a bimodal gene therapy approach for the treatment of ADA-deficient SCID
    Carbonaro-Sarracino, Denise A.
    Chun, Krista
    Clark, Danielle N.
    Kaufman, Michael L.
    Jin, Xiangyang
    Wang, Xiaoyan
    Kohn, Donald B.
    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2021, 20 : 765 - 778
  • [45] Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies
    Sun, Junjiang
    Hua, Baolai
    Chen, Xiaojing
    Samulski, Richard J.
    Li, Chengwen
    HUMAN GENE THERAPY, 2017, 28 (08) : 654 - 666
  • [46] Global CNS Gene Delivery in Non-Human Primates by Intra-CSF Administration: Evasion of Anti-AAV Neutralizing Antibodies but Not a Transgene-Specific CTL Response
    Gray, Steven J.
    Kalburgi, Sahana Nagabhushan
    McCown, Thomas J.
    Samulski, R. Jude
    MOLECULAR THERAPY, 2013, 21 : S46 - S46
  • [47] Effects of long-term expression of VEGF-A and Sema3A after gene delivery in vivo using AAV vectors
    Zacchigna, S
    Lucia, P
    Nikola, A
    Lorena, Z
    Sara, T
    Marina, D
    Mauro, G
    MOLECULAR THERAPY, 2004, 9 : S72 - S73
  • [48] Site-specific gene delivery to the vasculature in vivo using peptide-targeted adeno-associated virus (AAV) vectors
    Nicklin, SA
    White, SJ
    Büning, H
    Papadakis, ED
    Brosnan, MJ
    Hallek, M
    Baker, AH
    ATHEROSCLEROSIS, 2003, 169 (01) : 200 - 200
  • [49] Gene delivery to airway epithetiat cells in vivo:: a direct comparison of apicat and basotateral transduction strategies using pseudotyped lentivirus vectors
    Kremer, Karlea L.
    Dunning, Kylie R.
    Parsons, David W.
    Anson, Donald S.
    JOURNAL OF GENE MEDICINE, 2007, 9 (05): : 362 - 368
  • [50] Targeted, safe, and efficient gene delivery to human hematopoietic stem and progenitor cells in vivo using the engineered AVID adenovirus vector platform
    Yao, Jia
    Atasheva, Svetlana
    Wagner, Nicole
    Di Paolo, Nelson C.
    Stewart, Phoebe L.
    Shayakhmetov, Dmitry M.
    MOLECULAR THERAPY, 2024, 32 (01) : 103 - 123
12345